Gilgamesh Pharma Inc.
PrivateLast Round
Series A
Mar 24, 2026
Est. Valuation
$100M
Total Funding Raised
$212.73M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Gilgamesh Pharma Inc. operates in Healthcare & Life Sciences and is based in New York City, New York. Its latest recorded funding round was a Series A round in March 2026.
Gilgamesh Pharma Inc. is a clinical-stage neuroscience biotechnology company that develops innovative new chemical entities for the treatment of psychiatric and neurological disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Mental Health, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Gilgamesh Pharma Inc. Comparables
Compare Gilgamesh Pharma Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Sensorium Therapeutics | 85% | |
| Delix Therapeutics | 85% | |
| Reunion Neuroscience Inc. | 84% |
For institutional investors. Book with your work email.
Gilgamesh Pharma Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 24, 2026 | ||||
| Corporate Funding | May 13, 2024 | ||||
| Grant | Mar 14, 2024 | ||||
| Series B | Dec 15, 2022 | ||||
| Series A | May 6, 2021 | ||||
Accelerator | Aug 24, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Gilgamesh Pharma Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute on Drug Abuse | Grant |
| Pioneer Fund | Seed |
| Gaingels | Seed |
| Negev Capital | Series B |
| Noetic Fund | Series A |
| Route 66 Ventures | Series A, Series B |
| Gron Ventures | Series A, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 19, 2026
GM-3009, a novel ibogaine derivative for PTSD, is in early-stage clinical testing.
- Mar 24, 2026
$60M round completed.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- sells_assets_toAug 19, 2026
Gilgamesh Pharma Inc. sells its bretisilocin asset to AbbVie for up to $1.2B.
For institutional investors. Book with your work email.
Gilgamesh Pharma Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Gilgamesh Pharma Inc.'s valuation, stock price, and market status.
Is Gilgamesh Pharma Inc. a public or private company?
Gilgamesh Pharma Inc. is a private company.
What is the current stock price of Gilgamesh Pharma Inc.?
Gilgamesh Pharma Inc. is a private company, so its shares have no public market price. Caplight tracks Gilgamesh Pharma Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Gilgamesh Pharma Inc. worth (valuation)?
Gilgamesh Pharma Inc.'s valuation is estimated at $100.0M based on funding round data.
Can I buy Gilgamesh Pharma Inc. stock?
Gilgamesh Pharma Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Gilgamesh Pharma Inc.'s last funding round?
Gilgamesh Pharma Inc.'s most recent funding round was Series A on March 24, 2026.
Who are the main investors in Gilgamesh Pharma Inc.?
Key investors in Gilgamesh Pharma Inc. include Prime Movers Lab, Satori Neuro.
Will Gilgamesh Pharma Inc. IPO soon?
No public IPO plans have been announced for Gilgamesh Pharma Inc..
How can I track Gilgamesh Pharma Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Gilgamesh Pharma Inc.'s shares on secondary markets.